Chart Events
Performance Outlook
| Previous Close | 51.08 |
| Open | 50.56 |
| Bid | 51.18 x 1000 |
| Ask | 51.19 x 900 |
| Day's Range | 50.48 - 51.31 |
| 52 Week Range | 41.45 - 61.71 |
| Volume | |
| Avg. Volume | 20,192,709 |
| Market Cap | 286.419B |
| Beta (5Y Monthly) | 0.64 |
| PE Ratio (TTM) | 9.77 |
| EPS (TTM) | 5.22 |
| Earnings Date | Feb 06, 2023 - Feb 10, 2023 |
| Forward Dividend & Yield | 1.60 (3.23%) |
| Ex-Dividend Date | Nov 03, 2022 |
| 1y Target Est | 54.78 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for PFE
Related Research
- Pfizer, Inc.Analyst Report: Pfizer Inc.Pfizer is a leading global developer and manufacturer of pharmaceuticals and biotech drugs. Its products include oncology and immunology drugs, treatments for rare diseases, and vaccines.RatingFair ValueEconomic Moat24 days agoArgus Research
- Reuters
UPDATE 1-Pfizer to invest more than $2.5 bln to expand European manufacturing
Pfizer Inc is investing more than $2.5 billion at its drug making plants in Belgium and Ireland, gearing up to launch new products it hopes can replace lost revenue as patents expire and COVID-19 vaccine sales decline. The drugmaker said on Friday it plans to spend more than 1.2 billion euros ($1.26 billion) to expand its Puurs, Belgium, manufacturing site, matching the investment at its Dublin, Ireland, plant announced on Thursday.
- Simply Wall St.
Shareholders may not want to ignore the US$8.2m worth sales made by Pfizer Inc. (NYSE:PFE) insiders this past year
While Pfizer Inc. ( NYSE:PFE ) shareholders have had a good week with the stock up 4.6%, they shouldn't let their...
- Reuters
Pfizer to invest more than $2.5 bln to expand European manufacturing
Pfizer Inc is investing more than $2.5 billion at its drug making plants in Belgium and Ireland, gearing up to launch new products it hopes can replace lost revenue as patents expire and COVID-19 vaccine sales decline. The drugmaker said on Friday it plans to spend more than 1.2 billion euros ($1.26 billion) to expand its Puurs, Belgium manufacturing site, matching the investment at its Dublin, Ireland plant announced on Thursday. The Puurs site has played a key role in the production of COVID-19 vaccine shots Pfizer developed with its German partner BioNTech using the messenger RNA (mRNA) technology.
